Flagging the Forgetting/
Accelerating the development of New Molecular Bio Markers for Alzheimer's Disease
This project aims to develop an Indo-European network to accelerate the development of new molecular biomarkers for Alzheimer’s Disease (AD), in full agreement with the EMEA guidelines (EMEA/CHMP/SAWP/72894/2008 Corr), in coherence with the concept of biomarker “signatures” as followed by PharmaCog IMI project, EuroADNI initiative, supported by French Eurobiomed and Indian Biogenesis clusters. Objectives are to advance harmonisation in research on AD, to strenghtening bilateral S&T cooperation between Europe and India. Specific aims are to: Organize seminars, standardize diagnosis criteria and cognitive evaluation (ADNI battery), Implement and standardize biomarkers (CSF tau, Ptau, Abeta), harmonize ethical principles, identify new biomarkers by detecting a large diversity of proteins in plasma and CSF using state of the art proteomics techniques, to disseminate/exploit. The consortium comprises: An Indian memory Center and pharmacology team (Prof Borgohain, NIMS, Hyderabad), A French excellence research team for biomarkers, specific monoclonal antibody selection for diagnosis, theranostic and prognosis, system biology for multi-scale modelling in complex pathologies (CNRS Sysdiag, Dr Laune, Montpellier) and a French pharmacology team in France, coordinator of IMI PharmaCog (CNRS, INCM , UnivMed, Prof Blin, Marseille), A proteomics centre in Germany for biomarker discovery and validation, using neuroproteomics and bioinformatics (Prof Meyer, Bochum), A Portuguese Neuropharmacology department (Prof Sampaio, Lisbon) for regulatory aspects.